论文部分内容阅读
骨形态发生蛋白-7是一种多功能细胞因子,与相应受体结合后经信号转导发挥作用,受多种拮抗剂和激动剂的调控。肾间质纤维化是多种肾脏疾病进展到终末期肾衰竭的共同途径和主要病理基础。在多项慢性肾脏疾病动物模型的研究中,发现给予重组骨形态发生蛋白-7能够抑制或逆转肾小管间质纤维化,改善肾功能。骨形态发生蛋白-7可能通过维持肾小管细胞表型、逆转上皮-间质细胞转变、减少细胞外基质、抑制炎症等环节发挥抗纤维化作用。文中就重组骨形态发生蛋白-7在肾纤维化治疗中的研究进展进行综述。
Bone morphogenetic protein-7 (BMP-7) is a multifunctional cytokine that acts by signal transduction when bound to the corresponding receptor and is regulated by various antagonists and agonists. Renal interstitial fibrosis is the common pathway and the main pathological basis for the progression of many kidney diseases to end-stage renal failure. In a number of animal models of chronic kidney disease, recombinant bone morphogenetic protein-7 was found to inhibit or reverse tubulointerstitial fibrosis and improve renal function. Bone morphogenetic protein -7 may play an anti-fibrotic effect by maintaining the phenotype of renal tubular cells, reversing epithelial-mesenchymal transition, decreasing extracellular matrix and inhibiting inflammation. The article reviews the research progress of recombinant bone morphogenetic protein-7 in the treatment of renal fibrosis.